Percutaneous exclusion of the left atrial appendage in prevention of systemic embolism  by Šťásek, Josef et al.
Available online at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/crvasa
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 5 6 – e 1 6 10010-8650/$ - see fro
http://dx.doi.org/10
nCorresponding a
E-mail address:Review – Special issue: Novel methods in interventional cardiology and cardiac surgeryPercutaneous exclusion of the left atrial appendage in
prevention of systemic embolismJosef Sˇt’a´seka,n, Josef Bisa, Zdeneˇk Vaveraa, Jan Voja´cˇeka, Jaroslav Dusˇeka, Miroslav Brtkob,
Pavel Polansky´b, Petr Parˇı´zeka, Abdul Al Mawiria
aCharles University Prague, Ist Department of Medicine, Cardio-angiology, School of Medicine and University Hospital, Hradce Kra´love´,
Czech Republic
bDepartment of Cardiothoracic Surgery, University Hospital, Hradce Kra´love´, Czech Republica r t i c l e i n f o
Article history:
Received 9 May 2012
Received in revised form
25 May 2012
Accepted 25 May 2012
Available online 31 May 2012
Keywords:
Left atrial appendage
Systemic embolism
Atrial fibrillation
Amplatzer cardiac plug
Anticoagulation therapynt matter & 2012 The Cze
.1016/j.crvasa.2012.05.010
uthor. Tel.: þ420 4958311
stasek@fnhk.cz (J. Sˇt’a´sea b s t r a c t
Left atrial appendage is the most frequent place of blood clot formation in heart cavities.
The thrombus formation increases a risk of a systemic embolism especially in patients
with a permanent atrial fibrillation. The standard preventive treatment is the oral
anticoagulation therapy. Another possible a treatment is an exclusion of a left atrial
appendage. We present current overview a risks and benefits of surgical and percutaneous
elimination of a left atrial appendage. We present the first experience with Amplatzer
Cardiac Plug system in an elimination of a left atrial appendage. We concluded that an
exclusion of left atrial appendage could become a useful possibility of prevention of
systemic embolization in patients with an atrial fibrillation, but is not still an alternative
therapy for anticoagulation therapy at present.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Systemic embolism, especially cerebral embolism, is a very
serious health problem. Approximaly 15–20% of ischemicch Society of Cardiology.
11; fax: þ420 495833581.
k).strokes are caused by an atrial fibrillation (AF) according to
the literature. AF occurs in 3–5% of people older than 65 years
with a 5% risk of stroke per year. The risk increases up to 30%
per year in octogerians or elderly [1–4]. The most frequentPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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people with a permanent AF combined with the rheumatic
valve disease, LAA is a region of formation of thrombus in
about 57% of cases and in about 90% in cases of non-rheumatic
AF [4,5]. The oral anticoagulation therapy (AT) is nowadays a
standard treatment diminishing the risk of ischemic stroke.
Hart’s meta-analysis shows that AT decreases the risk of
ischemic stroke by about 64%, while the antiplatelet therapy
only by about 22% [6–9]. However a significant group of high risk
people with a permanent AF is contraindicated to AT and in
some other cases AT is unsatisfactory and insufficient [10].
The location of LAA has led to the idea that the risk of stroke
in patients with AF operated for a valve heart disease could beFig. 1 – AMPLATZER Cardiac Plug.
Fig. 2 – (a) and (b): TEE picture a
Fig. 3 – (a) and (b): Trareduced by eliminating LAA. Although a surgical elimination of
LAA has been made since late 1940s, there is still a lack of data
about benefits and effectiveness of this procedure. The stan-
dard techniques of the LAA elimination are the excision,
ligation, suture or stapler. In accordance to published studies,
the LAA elimination is not always successful. The range of
successful complete elimination fluctuates between 0–73%,
regarding a type of procedure [11–15]. It is evident that in a
standard clinical practice a success of LAA is influenced either
by a type, quality and accuracy of procedure.
Most recently, some less invasive thoracoscopic technics
have been invented and introduced into a clinical practice.
The LAA elimination is performed solely, or together with the
MAZE ablation of AF. The data are limited also in case of this
procedure [16–20].
The last possibility of the LAA elimination is the percuta-
neous closure via a transseptal puncture. The combined trans-
septal and transpericardial accesses are also tested—Lariats
Suture Delivery Device (Sentreheart, Inc.; Palo Alto, Calif).2. Percutaneous closure of a left atrial appendage
First experiences with the percutaneous closure of LAA were
released shortly after 2000—the first dedicated system was
PLAATO [21,22]. Meier et al. published first experiences with
the LAA closure by Amplatzer ASD Occluder in 2003 [23].
There are currently two dedicated systems on the
market—WATCHMAN (Atritech Inc., Plymouth, Minnesota)
and AMPLATZER Cardiac Plug (Amplatzers Cardiac Plugnd the LAA—measurement.
nsseptal puncture.
Fig. 4 – Access of the sheath through the atrial septum into
the LA.
Fig. 5 – Angiography of the LAA.
Fig. 6 – Device before its withdrawal from the sheath.
Fig. 7 – Lobe in the LAA.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 5 6 – e 1 6 1e158AGA Medical Corporation, a part of St. Jude Medical, Inc.; St.
Paul, Minneapolis). The AMPLATZER Cardiac Plug system
(Fig. 1) is used at our department, therefore a short descrip-
tion of the procedure with this device follows.
Transoesophageal echocardiography (TEE) is an important
first step in patients screened for the LAA closure. It is
necessary to measure the size, shape and position of LAA
in some distinct projections (Fig. 2(a) and (b)). The anatomic
variability of LAA is vast. The TEE examination is also
required immediately before the implantation of the device
in order to avoid casual thrombus in LAA. The routine and
safe transseptal puncture is crucial in the LAA closureprocess (Fig. 3a) and (b)). A stiff guiding wire is placed through
a transseptal catheter into a left atrium (LA), the most
optimally into a left pulmonary vein. Using this guiding wire,
a 8–13 F sheath is inserted into LA and then into LAA (Fig. 4).
LAA angiography in some distinct projections is suitable as
well (Fig. 5). The Amplatzer Cardiac Plug is made from Nitinol
mesh and consists of two parts. The first part is the lobe with
small hooks that is placed into a cavity of LAA, fixing the
device inside. The second part is the disk that closes a LAA
orifice. The device is introduced by a cable, as similarly as
with other Amplatzer devices (Fig. 1). After thorough assur-
ance of its position and stability the cable is unscrewed and
Fig. 8 – Device completely released in the LAA with cable.
Fig. 9 – Released device, the angiographic control of the
position.
Fig. 10 – Released device, TEE control of the position.
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drawal of the device is possible. Positioning and stability
verification of the plug is performed by TEE with a parallel
angiographic control (Figs. 6–10).
The procedure in our department is performed in an
analgosedation, another alternative is a general anesthesia.
Heparin (100 j/kg) is given during the procedure. No patient
died due to periprocedural complications. One patient had an
acute cardiac tamponade with necessity of surgical revision.
The surgeon found the contusion and hematoma on the
boundary between the upper left pulmonary vein and theLAA. The contusion was caused by the edge of sheath, which
passed through the septum only with heavy resistance. The
sheath then held onto the wall of LA after removing the wire.
However, the surgeon found no leak or bleeding. No other
serious complications occurred in our patients.
The dual antiplatelet therapy (Aspirin 100 mgþclopidogrel
175 mg/day) is used over the next three months following
the procedure and then Aspirin (100 mg) after that 3 months
period. We have no mortality in follow-up period of 3–20
months. A small flat thrombus was verified on the plug’s disk
in one patient, who prematurely quitted the dual antiplatelet
treatment without our approval. Two patients have trivial
leaks. No systemic embolism has occurred in any our patient.
Furthermore, no patient used Warfarin.3. Discussion
While considering the LAA exclusion, we should keep in
mind that the LAA is a region prone to thrombus formation in
some patients. However, the LAA has some important phy-
siological functions. It has a crucial positive role in a systolic
function of LA, improves a filling of a left ventricle and
thereby influences cardiac output. It has a buffer function
in liquid volume and pressure in a LAA. LAA elimination
increases both size and mean pressure in LA. LAA distention
helps to induce a diuresis. It has a certain role in a sensation
of thirst. A LAA is hormonally active, producing an atrial and
probably a brain natriuretic peptide [24].
The percutaneous closure of LAA is a tough procedure—it is
essential to manage routinely the transseptal puncture and
the implantation takes place in a very thin-wall cavity of LA
and LAA (0.4–1.5 mm). The procedure might be connected
with couple of complications (e. g. tamponade, device embo-
lization, a periprocedual stroke, air embolism), another pro-
blem could be a residual leak or thrombus formation on a
device. Sievert et al. [21] states that he had one tamponade in
a group of first 15 patients with PLAATO system. Ostmayer
et al. [25] states 97,3% primary success in a group of 111
patients with PLAATO. One patient died during the hospita-
lization. The pericardial effusion was verified in four patients,
two of them had tamponade. Hemothorax was documented
in one patient. Stroke occurred in 2.2% patients of the group.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 5 6 – e 1 6 1e160Six months after the procedure the LAA was totally occluded
in 98% of the patients. Sick et al. [26] published first experi-
ence with the WATCHMAN system in a group of 66 patients.
The LAA was totally occluded in 93% of patients 45 day after
the procedure. Two patients had device embolization, two
had tamponade, one had air embolization and one patient’s
occluder was damaged. Billowing thrombus was verified in
four cases (successfully treated by the anticoagulantion
therapy), transient ischemic attack (TIA) in two cases. Park
et al. [27] describes first experience with the Amplatzer
Cardiac Plug system. It was successful in 96% in a group of
143. Serious complications occurred in 10 cases (7%): peri-
procedural stroke (3x), device embolization (2x), tamponade
(5x).
PROTECT AF study [28,29] is the only randomized study up
to date. This study was drafted as a study of non-inferiority of
the percutaneous closure of LAA by the WATCHMAN system
against the standard AT by Warfarin. 707 patients with atrial
fibrillation and risk of stroke (CHADS2Z1) were randomized
in the rate of 2:1 (WATCHMAN 463:244 Warfarin). The mean
follow-up was 18 months. The combined end-point (neither
stroke, cardiovascular death or systemic embolism) was
detected in 3% of patients in WATCHMAN group and 4.9%
in Warfarin group. Non-inferiority of invasive procedure was
therefore proved.
From the primary safety end-point (device embolization,
tamponade, brain bleeding, gastrointestinal tract bleeding
with a necessity of usingZ2 transfusions), brain bleeding
occurrence was significantly higher in the Warfarin group
(2.5% vs. 0.2%) and also other types of bleeding were higher
(4.2% vs. 3.5%). Serious complications in the WATCHMAN
group were experienced in 12.3% of patients (tamponade
4.8%, periprocedural stroke 1.1% and device embolization
0.6%). The overall frequency of ischemic stroke was higher
in the WATCHMAN group (3% vs. 2%) due to periprocedural
stroke. Reddy et al. extended the assessment of the study of
about 460 patients from the WATCHMAN registry and eval-
uated separately the data from the second part of the
PROTECT AF study. Significant decrease in complications
was documented [30].4. Conclusions
(1) The percutaneous closure of LAA is an acceptable and
useful possibility of prevention of systemic embolization in
patients with an atrial fibrillation. (2) The procedure cannot
be considered as an alternative to the AT. Only those contra-
indicated to the AT or people with serious complications of
AT should be indicated to the percutaneous closure. Although
the PROTECT AF study proved non-inferiority elimination of
the LAA by the WATCHMAN system, incidence of periproce-
dural complications was quite disturbing. More data are
needed. (3) Because of the possibility of serious periproce-
dural complications, this procedure should only be per-
formed at departments with routine experience with the
transseptal puncture and the percutaneous interventions in
a LA. (4) In general, the elimination of LAA should be carefully
considered and undertaken only in patients with evidentdysfunction of the LAA. It should not be performed in patient
with a real possibility of sinus rhythm restoration.
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